Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Robust global demand for Oncotype DX and increased Cologuard orders are likely to have driven Exact Sciences' (EXAS) Q1 performance.

Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?

MADISON, Wis. , April 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its first quarter 2022 financial results after the close of the U.S. financial markets on April 26, 2022.

Exact Sciences schedules first quarter 2022 earnings call

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Exact Sciences (EXAS) Down 4.3% Since Last Earnings Report: Can It Rebound?

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

Exact Sciences (EXAS) Cologuard Sales Up but Costs Rise

Coinbase

Popular stockpicker Cathie Wood-led Ark Investment Management's top ten key bets — spread across clean energy, innovation, tech, healthcare, and space sectors that constitute nearly half of its investments are not faring well in 2022 — as the first quarter nears an.

Tesla, Coinbase, Exact Sciences And More: How Cathie Wood's Top 10 Bets Are Faring In 2022 So Far

Exact Sciences (EXAS) closed at $72.26 in the latest trading session, marking a +0.81% move from the prior day.

Exact Sciences (EXAS) Gains But Lags Market: What You Should Know

NEW YORK and MADISON, Wis., March 7, 2022 /PRNewswire/ -- Katie Couric, award winning journalist and colorectal cancer advocate who normalized talking about colon cancer more than two decades ago, today announced she has teamed up with Exact Sciences (NASDAQ: EXAS), the maker of Cologuard®, to highlight the urgent need for people to get screened.

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer

Exact Sciences Corp's (NASDAQ: EXAS) Q4 revenues increased 2% Y/Y to $473.8 million and beat the average Wall Street estimate of $449 million. Excluding COVID-19 testing revenues, which dropped 52% to $47.1 million, Exact's Q4 revenue increased 16%.

Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues

Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.

Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down

Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q4 2021 Results - Earnings Call Transcript

MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473.8 million for the fourth quarter ended Dec. 31, 2021 and $1,767.1 million for the full year ended Dec. 31, 2021.

Exact Sciences Announces Fourth Quarter 2021 Results

Intellia Therapeutics

UiPath

Roku

Block

Teladoc

Tesla

Unity Software

Zoom Video

Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains.  The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020, beating the Nasdaq's 43.6% return.

How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months?

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Exact Sciences (EXAS) Q4 Earnings Expected to Decline

MADISON, Wis., Feb. 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its fourth quarter 2021 financial results after the close of the U.S. financial markets on February 22, 2022.

Exact Sciences schedules fourth quarter 2021 earnings call

MADISON, Wis., Feb. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

Exact Sciences to participate in February investor conferences

MADISON, Wis., Jan. 18, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer (CRC) at specificity of 92.4% for negative samples confirmed by colonoscopy.

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

This top medical diagnostic stock took a big haircut in 2021.

Why Exact Sciences Stock Plunged in 2021

MADISON, Wis., Jan. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) announced today it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT).

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

MADISON, Wis., Jan. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $472 million and $475 million for the fourth quarter ended Dec. 31, 2021.

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences (EXAS) closed the most recent trading day at $75.66, moving +1.42% from the previous trading session.

Exact Sciences (EXAS) Gains As Market Dips: What You Should Know

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear

Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.

Exact Sciences' (EXAS) Oncotype DX Test Study Data Favorable

MADISON, Wis., Dec. 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium® (SABCS®) supporting the clinical value of the Oncotype DX Breast Recurrence Score test.

New Data Presented at SABCS® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making

Its positioning in cancer diagnostics is good, but it faces an important headwind.

News for Exact Sciences Stock (EXAS)